Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 2, 1999, Pages 151-156

  Della Torre, Paola ^a   Mazué, Guy ^a   Podestà, Arturo ^a   Moneta, Donatella ^a   Sammartini, Umberto ^a   Imondi, Anthony R ^b  

^a Pharmacia and Upjohn   (Italy)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Cardiotoxicity; Dexrazoxane; Doxorubicin

Indexed keywords

DOXORUBICIN; DRUG VEHICLE; LACTATE SODIUM; RAZOXANE;

ADOLESCENT; AGED; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG SAFETY; GROWTH INHIBITION; HEART PROTECTION; HEART WEIGHT; IMMATURITY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY MASS; LIVER WEIGHT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TESTIS ATROPHY; TRIACYLGLYCEROL BLOOD LEVEL; WEANING;

AGING; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CARDIOMYOPATHIES; CHELATING AGENTS; DOXORUBICIN; ERYTHROCYTES; GROWTH; LEUKOCYTES; MALE; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; RAZOXANE; WEANING;

EID: 0032903933     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050876     Document Type: Article

References (16)

1. Bertazzoli C, Bellini O, Magrini U, Tosana M (1979) Quantitative experimental evaluation of Adriamycin cardiotoxicity in the mouse. Cancer Treat Rep 63: 1877
2. Della Torte P, Podesta A, Pinciroli G, latropoulos M J, Mazué G (1996) Long-lasting effect of dexrazoxane against anthracycline cardioxicity in rats. Toxicol Pathol 24: 398
3. Herman EH, Ferrans VJ (1983) ICRF-187: reduction of chronic daunorubicin and doxorubicin cardiotoxicity in rabbits, beagle dogs and miniature pigs. Drug Exp Clin Res 9: 483
4. Herman EH, Ferrans VJ (1986) Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother Pharmacol 16: 102
5. Imondi AR, Della Torre P, Mazué G, Sullivan TM, Robbins TL, Hagerman LM, Podestà A, Pinciroli G (1996) Dose-response relationship of dexrazoxane for prevention of doxorubicin-induced cardiotoxicity in mice, rats, and dogs. Cancer Res 56: 4200
6. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sander SP (1991) Late cardiac effect of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324: 808
7. Mazué G, Iatropoulos M, Imondi A, Castellino S, Brughera M, Podestà A, Della Torre P, Moneta D (1995) Anthracyclines: a review of general and special toxicity studies. Int J Oncol 7: 713
8. Perkins WE, Schroeder RL, Carrano RA, Imondi AR (1982) Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig. Br J Cancer 46: 662
9. Rosenthal PE, Griffin TW, Hassey Dow K, Lingos TI, Maclawicz R, O'Connor L (1991) Complications of cancer and cancer treatment. In: Osteen RT (ed) Cancer manual, 8th edn. American Cancer Society, Boston, p 420
10. Schuler D, Horvath P, Koos R, Kajtar P, Zimonyl L, Virag I, Masat P, Garami M, Borsi JD (1997). Safety of dexrazoxane in children with ALL undergoing anthracycline therapy: preliminary results of a prospective pilot study. Pediatr Hematol Oncol 14: 93
11. Solcia E, Ballerini L, Bellini O, Magrini U, Bertazzoli C, Tosana G, Sala L, Balconi F, Rallo F (1981) Cardiomyopathy of doxorubicin in experimental animals. Factors affecting the severity, distribution and evolution of myocardial lesions. Tumori 67:461
12. Speyer JL, Green MD, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Jacquotte-Zeleniuch A, Wernz J, Felt F, Slater W, Blum R, Muggia F (I988) Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 319: 745
13. Steinhertz LJ, Steinhertz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266: 1672
14. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15: 1318
15. Swain SM, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gains RA (1997) delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-coniaining therapy. J Clin Oncol 15: 1333
16. Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, Dilsizian V. Jarosinski AN, Baits FM, Poplack DG, Horowitz ME (1996) Randomized trial of the cardioprotective agent ICRF-I87 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 14: 362